Introduction
Atherosclerosis involves the accumulation of lipids and inflammatory cells in the arterial intima forming plaques. Macrophages ingest lipids and elaborate inflammatory mediators that promote plaque progression and destabilization [1] . During atheroma initiation, macrophages accumulate primarily through infiltration of Ly6C high monocytes. In established plaques, however, macrophages renew through local proliferation rather than recruitment [13] . It is unknown whether prolonged interference with monocyte recruitment to established plaques can limit macrophage accumulation.
Spleen tyrosine kinase (SYK), a cytosolic signaling protein, binds to various receptors and adaptors containing immunoreceptor tyrosine-based activation motifs (ITAM). Integrin signaling in myeloid cells, for example, requires the ITAM-bearing DAP12 adaptor and subsequent SYK activation to induce cell adhesion [9, 16] . We showed that treatment with the orally available SYK inhibitor fostamatinib reduced inflammatory cell recruitment to the vessel wall and infiltration to sites of inflammation in low density lipoprotein receptor deficient (Ldlr -/-) mice. Consequently, these animals developed less atherosclerosis [5] . Of note, fostamatinib demonstrated significant improvement in ACR20 scores over placebo in two recent phase 3 trials with rheumatoid arthritis (RA) patients [5, 17] . The long-term effects of this SYK inhibitor on cardiovascular events in this high risk study population with chronic inflammation and accelerated atherosclerosis [4, 14] remains unknown.
The present study compared the efficacy of SYK inhibition in early and established atherosclerosis. We used Apoe -/-mice, which develop highly inflammatory atherosclerosis characterized by hypercholesterolemia-associated monocytosis [15] . The myelopoietic growth factors GM-CSF and IL-3 stimulate monocyte production in atherosclerosis [12] . Their receptors share a common beta chain (CBS) that associates with SYK [18] . We hypothesized that SYK inhibition by fostamatinib would reduce monocytosis and cell adhesion, and provide us with a tool to lower monocyte contribution to the plaque in early and late atherosclerosis.
Methods
Animal models
6-week-old female Apoe
-/-mice (B6.129P2-Apoe tm1Unc / J) were purchased from Charles River (Calco, Italy) and consumed a high cholesterol diet (1.25 % cholesterol; D12108 mod., Ssniff GmBH, Soest, Germany) ad libitum for 8 and 20 weeks, respectively, as indicated. Fostamatinib disodium (Astra Zeneca, UK) without carrier was incorporated at 0.3 % (w/w) into the diet as previously described [6] . 1 mg BrdU per mouse (BD Bioscience, San Jose, CA, USA) was injected intravenously 2 h before euthanasia. Intravital microscopy of mesenteric veins was performed 3 h after intraperitoneal stimulation with TNFa. Ly6C high monocytes were mobilized into peripheral blood by intravenous injection of 300 ng CCL2 (R&D System, Minneapolis, MN, USA). 1 lm large green fluorescent beads (Fluoresbrite YG plain microspheres, Polysciences Inc., Eppelheim, Germany), diluted 1:4 in sterile PBS, were injected intravenously for in vivo cell labeling and tracking. Mice were housed under specific pathogen-free conditions and procedures approved by the Animal Care Committee of the University of Freiburg and the Regional Council (G-12/083).
Histology
Aortic roots were embedded in OCT Tissue Tek (Sakura Finetek, Tokyo, Japan) for sectioning and staining with specific antibodies that are listed in the supplemental method section. Abdominal aortas were pinned for Oli-red O en face staining.
Flow cytometry and cell sorting
Cells isolated from the blood, spleen, bone marrow and aorta were stained with specific antibodies and dyes that are listed in the supplemental method section. The APC Brdu Flow Kit detected intracellular BrdU incorporation (BD Bioscience, San Diego, CA, USA) according to the manufacturer's instructions. Intracellular phospho-SYKTyr519/520 (Cell Signaling Technology, Boston, MA, USA) was evaluated in fixed and permeabilized (ebioscience, San Jose, CA, USA) bone marrow and blood cells. Data were recorded on a BD Facs Canto II (BD Bioscience, San Diego, CA, USA). Monocytes and macrophages were sorted with a BD Facs Aria III (BD Bioscience, San Diego, CA, USA).
Colony forming cell assay
Bone marrow cells were isolated from the femur and resuspended in Mouse Methylcellulose Complete Medium (R&D, Minneapolis, MN, USA) at 10 5 cells/ml. Cells were stimulated with 10 ng/ml GM-CSF and 10 ng/ml IL3 (Peprotech, Rocky Hill, NJ, USA) in the presence of the vehicle DMSO 0.1 %, 0.1uM R406 in DMSO 0.1 % and 1lM R406 in 0.1 % DMSO, respectively, as indicated. Cells were incubated at 37°C and 5 % CO 2 for 5 days according to the manufacturer's instructions and the number of colonies per 35 mm culture plate was counted under the microscope.
Cell culture and transwell assay

Ly6C
high monocytes isolated from the blood and spleen were stimulated with 30 ng/ml M-CSF (Peprotech, Rocky Hill, NJ, USA) in normal culture media (RPMI-1640, 10 % FCS, NEAA, 1 % PenStrep) as indicated. Ly6C high monocytes isolated from the bone marrow were differentiated into macrophages with 30 ng/ml M-CSF in normal culture media over 7 days and then stimulated with 10 lg/ ml human DiI-medium oxidized LDL (Kalen Biomedical, Montgomery Village, MD, USA) for 16 h in a minimal medium (2 % FCS in RPMI without growth factor supplements). Foam cell formation was evaluated by microscopy and flow cytometry. Bone marrow monocytes, isolated with the EasySep Mouse Monocyte Isolation Kit (Stemcell Technologies, Cologne, Germany) according to the manufacturer's instructions, were allowed to migrate for 3 h in a transwell chamber (2 9 10 5 cells per well; Costar 6.5 mm Transwell inserts with 5 lm pore membrane, Corning, Kennebunk, ME, USA) stimulated by CCL2 20 ng/ml, CCL5 20 ng/ml (R&D System, Minneapolis, MN, USA) or BSA 20 ng/ml as control. Cells in the lower chambers were quantified with an automated cell counter (Z2 analyzer, Beckman Coulter, Inc., Brea, CA, USA).
RNA isolation and real-time PCR
Cells were sorted into RLT/b-mercaptoethanol for subsequent RNA isolation using the RNeasy Micro Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. The Oviation PicSL WTA System V2 (NuGEN, San Carlos, CA, USA) was used for reverse transcription and cDNA amplification according to the manufacturer's instructions. Quantitative TaqMan-PCR was run on a Bio-Rad CFX96 Touch Real-Time PCR System (Bio-Rad Laboratories, Hercules, CA, USA). The specific TaqMan probes used are listed in the supplemental method section.
Statistics
Results are presented as mean ± SEM. Differences between 2 groups were evaluated by the unpaired Student's t test if they passed the Kolmogorov-Smirnov normality test or otherwise by the non-parametric Mann-Whitney test as indicated. Differences between more than 2 groups were evaluated by Kruskal-Wallis test with Dunn's multiple comparison test. p values B0.05 denote significant changes.
Results
SYK inhibition attenuates atherosclerotic plaque development in Apoe
2/2 mice 6-week-old Apoe -/-mice, still devoid of atherosclerosis, consumed a high cholesterol diet (HCD) supplemented with or without 0.3 % (w/w) SYK inhibitor fostamatinib for 8 weeks. At this point, we observed de novo plaque formation in the aortic root and abdominal aorta. Histologic analysis revealed that SYK inhibition markedly reduced overall lesion size, lipid and macrophage content in the aortic root and abdominal aorta, respectively (Fig. 1a-d) , despite similar plasma cholesterol levels (Supplemental Table 1 ). Flow cytometric analysis of aortic tissue lysates confirmed a significant reduction in Ly6C high monocyte and macrophage numbers (Fig. 1e, f) .
SYK inhibition reduces medullary and extramedullary myelopoiesis in atherosclerotic Apoe 2/2 mice
In accord with reduced cell counts in the aorta fostamatinib prevented the rise in circulating Ly6C high monocytes associated with hypercholesterolemia and atherogenesis (Fig. 2a) . We queried the possible mechanisms. First, Ly6C high monocyte numbers failed to increase in the bone marrow and spleen after 8 weeks of HCD with fostamatinib intake ( Fig. 2b) indicating hampered medullary and extramedullary myelopoiesis. Treatment with the SYK inhibitor lowered both the percentage of common myeloid progenitors (CMP) that incorporated BrdU and the frequency of their progeny, the macrophage dendritic cell progenitors (MDP), that give rise to monocytes, in the bone marrow and spleen (Fig. 2c, Supplemental Figure 1 ). Secondly, we found no signs of increased myelotoxicity with fostamatinib as assessed by Annexin V and PI staining (Fig. 2d) . Lastly, fostamatinib-treated and control mice showed similar CCR2 expression levels on Ly6C high monocytes in the bone marrow and no difference in their mobilization upon intravenous CCL2 administration (Fig. 2e, f) . These data indicate that fostamatinib inhibited hypercholesterolemia-associated inflammatory monocyte production.
SYK inhibition blocks GM-CSF/IL-3 stimulated myelopoiesis
Increased medullary and extramedullary monocyte production in Apoe -/-mice results from impaired cholesterol efflux and heightened surface expression of the common beta subunit of the GM-CSF/IL-3 receptor (CBS) on progenitor cells [10, 12, 19] . GM-CSF and IL-3 stimulate myeloid progenitor cell proliferation and SYK binds to the CBS for signal transduction [18] . We observed SYK phosphorylation at Tyr 519/520 associated with kinase activation in bone marrow CMP of Apoe -/-mice in response to stimulation with GM-CSF and IL-3. R406, the active metabolite of fostamatinib, limited GM-CSF/IL-3 induced SYK autophosphorylation (Fig. 3a) . SYK inhibition by R406 reduced colony formation by bone marrow cells stimulated with GM-CSF and IL-3 in line with our in vivo data ( Fig. 3b) . 
SYK inhibition attenuates monocyte infiltration and differentiation but not macrophage egress from atherosclerotic lesions
We next studied possible local effects of fostamatinib on lesional macrophage accumulation apart from monocyte production and mobilization. Consumption of HCD supplemented with 0.3 % fostamatinib for 4 days did not lower the number of leukocytes in the circulation but reduced their rolling along and adhesion to the intimal surface as assessed by intravital microscopy of TNFa stimulated mesenteric veins (Fig. 4a) . SYK inhibition, however, did not interfere with CCL2 and CCL5 directed monocyte migration in a transwell chamber (Fig. 4b) . The reduced number of lesional macrophages observed in fostamatinib-treated Apoe -/-mice ( result from reduced monocyte availability inside the lesion but also from impaired monocyte to macrophage differentiation or increased macrophage egress. Monocyte to macrophage differentiation depends on M-CSF. Stimulation of mature Ly6C high monocytes isolated from the blood and spleens of Apoe -/-mice with M-CSF induced SYK activation and phosphorylation at Tyr 519/520 that was abrogated by R406 (Fig. 4c) . Consequently, overnight culture of sorted Ly6C high monocytes with M-CSF and SYK inhibitor R406 blocked their differentiation into live F4/80 high macrophage-like cells (Fig. 4d) . To evaluate macrophage egress from atherosclerotic lesions we injected fluorescent beads, as previously described [11] , into young Apoe -/-mice that had just been placed on HCD 4 days previously (Fig. 4e) . Within 6 days myeloid cells had cleared the blood from circulating beads and infiltrated the nascent plaques (Fig. 4f) . Fostamatinib treatment was started at this time point in one group while the other group continued on HCD for another 8 weeks, thus avoiding any influence of the drug on the initial cell mediated accumulation of beads in lesions (Fig. 4e) . The beads are nondegradable and can only leave the lesions within emigrating phagocytes [11] . Therefore, the number of beads remaining in the lesion inversely correlates with macrophage egress. 8 weeks of fostamatinib treatment did not change the number of beads in lesions but still reduced the lesional macrophage content (Fig. 4g, Supplemental  Figure 2 ). We concluded that SYK inhibition mainly limited the number of infiltrating monocytes and their differentiation but not macrophage emigration from atherosclerotic lesions.
SYK inhibition exerts subtle effects on macrophage foam cell formation and inflammation
Macrophages accumulate lipids in atherosclerotic lesions and develop into foam cells. We tested if SYK inhibition affected foam cell formation. To this end, we generated Ly6C high monocyte derived macrophages that were incubated with DiI-labeled oxidized low density lipoprotein (DiI-oxLDL) overnight in the presence or absence of SYK inhibitor R406. The number of macrophages in culture remained unchanged, and all viable macrophages ingested oxLDL, though SYK inhibition reduced the mean fluorescence intensity of DiI by one-third (Fig. 5a, b) , similar to what had previously been observed with other lipoprotein modifications [2] . We next asked whether fostamatinib altered the inflammatory phenotype of monocytes and macrophages in the context of atherosclerosis. Macrophages and Ly6C high monocytes were sorted from atherosclerotic aortas alongside Ly6C high monocytes from the blood after 8 weeks of HCD with our without fostamatinib. RNA was isolated for gene expression analysis. Overall, fostamatinib exerted rather subtle and fluctuating changes of the inflammatory profile in all cell types tested, except for significantly reduced (pro-)IL-1b expression by macrophages (Fig. 5c) .
SYK inhibition fails to prevent plaque progression
Next, we asked whether SYK inhibition by fostamatinib could modulate progression of established plaques. Apoe -/-mice consumed a HCD for 8 weeks to allow plaque formation throughout the aorta (common group). Then mice were randomized to either HCD alone or HCD supplemented with 0.3 % (w/w) fostamatinib for another 12 weeks (Fig. 6a) . Again, treatment with fostamatinib abrogated the continuous rise of Ly6C high monocytes in the blood, bone marrow and spleen (Fig. 6b, c) . In contrast, fostamatinib intake did not alter lesion progression in the root and abdominal aorta. Lesional lipid and macrophage contents did not differ between groups (Fig. 6d-g ). To address the dissociation between circulating monocytes and lesional macrophage accumulation we quantified macrophage proliferation and cell death in aortic root sections. Fostamatinib treatment did not change the percentage of proliferating Ki67
? and apoptotic TUNEL ? macrophages in the plaque (Fig. 6h , i, Supplemental Figure 3 ).
Discussion
We show here that SYK inhibition by fostamatinib differentially interfered with the turnover and accumulation of monocytes and macrophages in atherosclerotic lesions on multiple levels. Fostamatinib impaired hypercholesterolemia-associated monocytosis stimulated by GM-CSF and IL-3 in Apoe -/-mice. In concert with reduced integrin-mediated cell adhesion [6, 9, 16] and hampered M-CSF-dependent macrophage differentiation, fostamatinib potently inhibited the early accumulation of lesional macrophages and the development of new atherosclerotic lesions by more than 70 %. Chemoattraction mediating high monocytes isolated from atherosclerotic aortas and blood, respectively, after 8 weeks of HCD in control and fostamatinib 0.3 % treated Apoe -/-mice (n = 6 per group). Results are presented as mean ± SEM percent change of marker expression in fostamatinib-treated mice compared to controls. *p B 0.05, t test. Other changes are statistically not significant monocyte/macrophage mobilization and migration involves G-protein-coupled receptor signaling [8, 20] independent of SYK and, therefore, may have remained unaffected. Our findings agree with the concept that macrophages in early atherosclerosis directly derive from infiltrating Ly6C high monocytes [7] . In established lesions, however, local foam cell proliferation rather than monocyte recruitment and differentiation dominates macrophage turnover [13] . SYK inhibition by fostamatinib, when started after lesions had already formed, still reduced Ly6C high monocytosis by about 50 %. Fewer monocytes, however, did not translate into reduced macrophage accumulation in advanced lesions. In fact, lesions continued to grow throughout the aorta by more than 50 % even with fostamatinib treatment. Half the amount of circulating Ly6C high monocytes might still suffice to sustain the macrophage pool in atherosclerotic lesions of fostamatinib-treated mice. We propose, however, that the failure to influence intraplaque macrophage proliferation, or cell death or egress rendered fostamatinib treatment ineffective in established disease (Fig. 7) . While GM-CSF/IL-3 stimulate myeloid progenitor cell proliferation via SYK, macrophage proliferation in more advanced lesions does not depend on GM-CSF/IL-3 signaling [13] . Rheumatoid arthritis and atherosclerosis share important common pathogenic mechanisms, and GM-CSF drives monocytosis in experimental rheumatoid arthritis [3] . When rheumatoid patients are treated with fostamatinib blood monocyte levels drop by 36 % [5] .
Our study indicates that the treatment of atherosclerosis may require disease stage specific approaches. Interventions directed against monocyte production and recruitment may limit early lesion formation or acute aggravation. In advanced lesions, however, when local proliferation dominates macrophage accumulation, targeting cell division itself or the respective stimulators may prove more effective. This concept, if applicable to humans, has major clinical implications as patients with atherosclerosis usually become symptomatic only after plaques have already formed. 
